Jacqualyn A Fouse - Net Worth and Insider Trading
Jacqualyn A Fouse Net Worth
The estimated net worth of Jacqualyn A Fouse is at least $3 Million dollars as of 2023-03-28. Jacqualyn A Fouse is the see remarks of Celgene Corp and owns about 18,664 shares of Celgene Corp (CELG) stock worth over $2 Million. Jacqualyn A Fouse is also the CEO of Agios Pharmaceuticals Inc and owns about 41,722 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $928,315. Details can be seen in Jacqualyn A Fouse's Latest Holdings Summary section.
Transaction Summary of Jacqualyn A Fouse
Jacqualyn A Fouse Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jacqualyn A Fouse owns 5 companies in total, including Incyte Corp (INCY) , Dick's Sporting Goods Inc (DKS) , and Bunge Ltd (BG) among others .
Click here to see the complete history of Jacqualyn A Fouse’s form 4 insider trades.
Insider Ownership Summary of Jacqualyn A Fouse
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2017-11-14 | director |
| DKS | Dick's Sporting Goods Inc | 2014-04-03 | director |
| BG | Bunge Ltd | 2009-09-02 | Chief Financial Officer |
| AGIO | Agios Pharmaceuticals Inc | 2017-12-03 | director |
| PRGO | Perrigo Co PLC | 2013-12-18 | director |
Jacqualyn A Fouse Latest Holdings Summary
Jacqualyn A Fouse currently owns a total of 2 stocks. Among these stocks, Jacqualyn A Fouse owns 18,664 shares of Celgene Corp (CELG) as of May 21, 2012, with a value of $2 Million and a weighting of 68.52%. Jacqualyn A Fouse also owns 41,722 shares of Agios Pharmaceuticals Inc (AGIO) as of November 13, 2019, with a value of $928,315 and a weighting of 31.48%.
Latest Holdings of Jacqualyn A Fouse
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CELG | Celgene Corp | 2012-05-21 | 18,664 | 108.24 | 2,020,191 |
| AGIO | Agios Pharmaceuticals Inc | 2019-11-13 | 41,722 | 22.25 | 928,315 |
Holding Weightings of Jacqualyn A Fouse
Jacqualyn A Fouse Form 4 Trading Tracker
According to the SEC Form 4 filings, Jacqualyn A Fouse has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the acquisition of 2,000 shares on May 21, 2012, which cost Jacqualyn A Fouse around $68,920.
According to the SEC Form 4 filings, Jacqualyn A Fouse has made a total of 1 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Agios Pharmaceuticals Inc is the acquisition of 40,322 shares on November 13, 2019, which cost Jacqualyn A Fouse around $1 Million.
Insider Trading History of Jacqualyn A Fouse
- 1
Jacqualyn A Fouse Trading Performance
GuruFocus tracks the stock performance after each of Jacqualyn A Fouse's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jacqualyn A Fouse is 16.53%. GuruFocus also compares Jacqualyn A Fouse's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jacqualyn A Fouse within 3 months outperforms 6 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Jacqualyn A Fouse's insider trading performs compared to the benchmark.
Performance of Jacqualyn A Fouse
Average Relative Return
28.83%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | 5.88 | 16.53 | 22.55 | 28.83 | 48.2 | 38.73 |
| Relative Return to S&P 500(%) | 6.34 | 13.47 | 17.32 | 13.77 | 29.64 | 23.21 |
Jacqualyn A Fouse Ownership Network
Ownership Network List of Jacqualyn A Fouse
Ownership Network Relation of Jacqualyn A Fouse
Jacqualyn A Fouse Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Jacqualyn A Fouse is the director of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Jacqualyn A Fouse made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Jacqualyn A Fouse Mailing Address
Above is the net worth, insider trading, and ownership report for Jacqualyn A Fouse. You might contact Jacqualyn A Fouse via mailing address: C/o Dick's Sporting Goods, 345 Court Street, Coraopolis Pa 15108.
